TITLE:
Natural History, Outcomes and Antibiotic Treatment for Ventilator-Associated Tracheobronchitis in Critical Ill Patients
AUTHORS:
Yuxiu Lei, Jana Hudcova, Jawad Rashid, Akmal Sarwar, Wendy Gillespie, Carol Finn, Marie Goggin, Mohamed B. Omran, Edward Boroda, Donald E. Craven
KEYWORDS:
Ventilator-Associated Tracheobronchitis (VAT) and Pneumonia (VAP), Bacterial Pathogens, Semi-Quantitative Endotracheal Aspirate (SQ-ETA) Cultures, Antibiotic Therapy
JOURNAL NAME:
Modern Research in Inflammation,
Vol.5 No.1,
February
29,
2016
ABSTRACT: We assessed incidence and
outcomes of patients with ventilator-associated respiratory infections (VARI)
due to tracheobronchitis (VAT) and pneumonia (VAP), including length of
intensive care unit (ICU) stay and ventilator days. We also examined pathogens,
rate of progression from VAT to VAP, and impact of antibiotic therapy for VAT.
Data analysis included 234 patients, 100 patients (43%) had at least moderate
(+++) bacterial growth in their semi-quantitative endotracheal aspirate
(SQ-ETA) cultures. VAT and VAP were each diagnosed in 34 (15%) patients. Staphylococcus aureus was the most common pathogen isolated
and had the highest rate of progression from VAT to VAP. Seven (21%) of the 34
patients were diagnosed with VAT that later progressed to VAP in averaged 3
days. Patients diagnosed with VAT had significantly more ventilator days (9 vs
6, p p p